Daniel Tan M.D.

Daniel is currently Director, Clinical transformation under the National Healthcare Group’s Clinical and Academic Development. He currently leads the Value Based Care team at NHG, the goal of which is to offer exceptional care with great clinical outcomes at the most affordable rates. Daniel is equally excited working on Digital Pathology with the Anatomical Pathology Department, bringing state of the art technology and uplifting a key diagnostic service into the digital era. Daniel was past Chief Medical Officer at Ventureblick, a startup incubator. Prior to that he was Chief Executive Officer, Parkway Laboratories Ltd as well as CEO of Angsana Molecular and Diagnostics Laboratory Pte Ltd, a subsidary of IHH. Daniel's past role as Assistant Chief Operating Officer for the National University Heart Centre, Singapore (NUHCS) and he oversaw the running of inpatient services comprising of 122 cardiac beds across 3 General Cardiac Wards and 2 Intensive Care Units at the National University Hospital (NUH). Daniel was one of the core leaders for Research under the NUHCS Centre Grant at the Cardiovascular Research Institute and was the Principal Investigator of a $2.5 million Care At Home Innovation Grant which piloted a new home care model using IT as an enabler for patient to be better managed at home. Daniel completed the 2016 Stanford Executive Program under NUHS's Academic Medicine Development award scholarship. Prior to his return to clinical services, Daniel served as the Director in the Policy and Legislative office at Health Sciences Authority which regulates all pharmaceutical and medical device products. During his tenure he provided technical expertise for the regulation of high risk medical devices and the formulation of regulatory policies that governs new health products. Daniel has garnered extensive experience in Biomedical R&D with his service at the Genome Institute of Singapore (GIS) where he served as the Deputy Director for Research Operations and held several concurrent portfolios including leading Singapore's first National Tissue Repository, the Singapore Tissue Network and he also managed a $45 million 5 year Infrastructure fund under the Singapore Cancer Syndicate.